The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

GlaxoSmithKline has begun a phase III clinical study that will compare comparing its drug Tykerb with Herceptin in the treatment of early breast cancer. The trial will measure which cancer cells disappear in the breast following treatment with Tykerb and/or Herceptin before surgery in women with early-stage breast cancer whose tumours overexpress the HER2 protein.

Comments are closed.

Of Interest